Why I’m avoiding these 3 FTSE 100 stocks in 2020

G A Chester sees different issues with these three FTSE 100 (INDEXFTSE:UKX) stocks, but valuations are the acid test.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a number of FTSE 100 stocks I think could disappoint investors in 2020. Among them are AstraZeneca (LSE: AZN), St. James’s Place (LSE: STJ) and Scottish Mortgage Investment Trust (LSE: SMT). Here’s why I’m avoiding these three.

Dubious core strength

AstraZeneca’s management has maintained the core earnings per share (EPS) guidance it gave at the start of the year of $3.50-$3.70 for 2019. At the midpoint and current exchange rates, this gives a price-to-earnings (P/E) ratio of 26.5 at a share price of 7,300p.

This is a huge premium to Footsie pharma peers GlaxoSmithKline and Hikma Pharmaceuticals, which trade at P/Es of 14.4 and 17.7 respectively. Furthermore, I’d argue AZN’s core EPS, on which the 26.5 P/E is based, grossly overstates its real core earnings, and that the true P/E is nearer a jaw-dropping 40.

This is because I exclude one-off profits from the divestment of non-core assets, which can’t go on forever but which AZN books as core operating profit. I also include legal costs (a routine expense in operating a big pharma company), which AZN excludes. AZN looks overvalued to me on its own core EPS measure, but grossly overvalued on what I consider its true core earnings.

Iffy business model

I’m avoiding wealth manager St. James’s Place on a view that it’s not only overvalued, but also has an iffy business model, and will have to change, with profit-margin-sapping consequences.

At a share price of around 1,100p, STJ’s P/E is 32.4 on forecast EPS of 34p for 2019. This earnings multiple is far too high, in my opinion. Furthermore, a valuation of more than 3% of funds under management (FUM) has proved a trusty indicator of overvaluation, in my experience. With a market capitalisation of £5.88bn, and FUM of £112.82bn, STJ is valued at 5.2% of FUM.

The company’s management fees and exit fees are excessive, in my view. Investors haven’t worried too much about this, seeing their portfolios increase in value over the last 10 years of rising markets, but are likely to pay a lot more attention in a downturn. Furthermore, with investors generally becoming a lot savvier about the corrosive effect of fees on returns, I think STJ will ultimately have to reset its margins.

Bonkers

It’s a peculiar and persistent feature of the UK stock market that some investment trust or another will rise from the FTSE 250 to the FTSE 100. However, no trust in history has gained sufficient critical mass to maintain its position in the top index.

Scottish Mortgage is the current representative in the FTSE 100. It’s achieved its status by a combination of high returns (471% over the last 10 years) and increasing popularity with investors (taking its shares to a premium to net asset value (NAV)).

The company has surfed on the outperformance of the US market and tech sector, holding a number of the so-called FAANG stocks, and the likes of Illumina and Tesla. The managers of the trust have borrowed money to gear returns (gearing is currently 9%), and remain optimistic on the outlook.

Personally, I think the valuations of many of the underlying holdings are bonkers. I fear a de-rating, SMT’s NAV dropping, gearing working negatively, and the shares moving to a wide discount to NAV. If so, SMT will become another in the long history of investment trusts failing to maintain a place in the FTSE 100.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Tesla. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

How I invested my first £1,000 in FTSE shares… and the mistakes I made

It can be intimidating investing for the very first time. Here, I share my first £1,000 investment and what mistakes…

Read more »

Mature couple in a discussion while eating a meal in a restaurant.
Investing Articles

How to invest £290 a month in UK shares for an income that aims to beat the State Pension

UK shares can offer a lucrative path for investors seeking a retirement income stream that beats the State Pension. Zaven…

Read more »

Aviva logo on glass meeting room door
Investing Articles

Aviva’s share price has left rivals in the dust. Here’s why it’s still good value

Mark Hartley explains why he feels his Aviva shares continue to offer excellent value even after five years of rapid…

Read more »

Investing Articles

2 excellent investment trusts to consider for an ISA or SIPP

This pair of investment trusts would offer a SIPP or ISA exposure to what could be a very large global…

Read more »

Tree lined "tunnel" in the English countryside of West Sussex in autumn
Investing Articles

How much is needed in an ISA to target a £3,150 monthly passive income?

Ben McPoland explains why it's not pie in the sky to aim for chunky ISA passive income, and also highlights…

Read more »

UK money in a Jar on a background
Investing Articles

Got a spare £3 a day? Here’s the passive income you could earn from it!

A few pounds a day might not seem like much. But, as our writer explains, it could help generate hundreds…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

Here’s how a small dividend stock ISA could produce £1,400 in passive income a year

Investing in dividend stocks can be a great way to generate a second income. And if they're held in an…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Here’s how Barclays shares could climb another 40%

Stock markets are clouded by geopolitical threats at the moment, but Barclays' shares could be heading for a further upwards…

Read more »